z-logo
open-access-imgOpen Access
Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities
Author(s) -
Alison E. Casey,
Ankit Sinha,
Rajat Singhania,
Julie Livingstone,
Paul Waterhouse,
Pirashaanthy Tharmapalan,
Jennifer Cruickshank,
Mona Shehata,
Erik Drysdale,
Hui Fang,
HyeYeon Kim,
Ruth Isserlin,
Swneke D. Bailey,
Tiago da Silva Medina,
Geneviève Deblois,
Yu-Jia Shiah,
Dalia Baršytė-Lovejoy,
Stefan O.P. Hofer,
Gary D. Bader,
Mathieu Lupien,
C.H. Arrowsmith,
Stefan Knapp,
Daniel D. De Carvalho,
Hal K. Berman,
Paul C. Boutros,
Thomas Kislinger,
Rama Khokha
Publication year - 2018
Publication title -
the journal of cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.414
H-Index - 380
eISSN - 1540-8140
pISSN - 0021-9525
DOI - 10.1083/jcb.201804042
Subject(s) - biology , progenitor cell , stem cell , chromatin , transcription factor , epigenetics , transcriptome , computational biology , progenitor , cell , cellular differentiation , proteomics , microbiology and biotechnology , genetics , dna , gene , gene expression
The mammary epithelium depends on specific lineages and their stem and progenitor function to accommodate hormone-triggered physiological demands in the adult female. Perturbations of these lineages underpin breast cancer risk, yet our understanding of normal mammary cell composition is incomplete. Here, we build a multimodal resource for the adult gland through comprehensive profiling of primary cell epigenomes, transcriptomes, and proteomes. We define systems-level relationships between chromatin-DNA-RNA-protein states, identify lineage-specific DNA methylation of transcription factor binding sites, and pinpoint proteins underlying progesterone responsiveness. Comparative proteomics of estrogen and progesterone receptor-positive and -negative cell populations, extensive target validation, and drug testing lead to discovery of stem and progenitor cell vulnerabilities. Top epigenetic drugs exert cytostatic effects; prevent adult mammary cell expansion, clonogenicity, and mammopoiesis; and deplete stem cell frequency. Select drugs also abrogate human breast progenitor cell activity in normal and high-risk patient samples. This integrative computational and functional study provides fundamental insight into mammary lineage and stem cell biology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom